Provigil vs Vyvanse: Real-World Evidence Comparison

What Each Drug Is and How It Works

Modafinil (Provigil) promotes wakefulness by inhibiting dopamine reuptake at the DAT transporter, while also increasing extracellular norepinephrine, histamine, and orexin signaling. Lisdexamfetamine (Vyvanse) is a prodrug converted by red-blood-cell hydrolysis to d-amphetamine, which then floods the synapse with dopamine and norepinephrine by reversing transporter direction. The two drugs share dopamine involvement but differ sharply in magnitude and mechanism.

Modafinil's Mechanism

Modafinil produces a relatively modest dopamine surge compared with classic amphetamines. Positron-emission tomography studies have shown DAT occupancy in the range of 50 to 60% at therapeutic doses, which is lower than the 70 to 80% occupancy associated with amphetamine's reinforcing properties. Because the dopamine increase is slower and more diffuse, modafinil's subjective "high" is minimal, which is part of why the DEA placed it in Schedule IV rather than Schedule II. The FDA label for modafinil notes that the drug's precise mechanism "is unknown" but that it "does not appear to alter the release of either dopamine or norepinephrine" in ways identical to amphetamine class drugs.

Lisdexamfetamine's Mechanism

Lisdexamfetamine releases free d-amphetamine gradually because the prodrug conversion is rate-limited by enzymatic hydrolysis, flattening the concentration peak compared with immediate-release amphetamine salts. Once converted, d-amphetamine reverses the dopamine transporter and vesicular monoamine transporter 2 (VMAT2), producing large synaptic dopamine and norepinephrine increases. The FDA prescribing information for Vyvanse lists mean Tmax for d-amphetamine at 4.4 hours, which reflects this extended absorption profile. This slower rise is the pharmacokinetic basis for its lower compared-with-dextroamphetamine abuse liability, though it remains a Schedule II substance.

Clinical Trial Evidence for Cognitive Outcomes

No published randomized controlled trial has put modafinil and lisdexamfetamine head-to-head. Conclusions about relative efficacy must be drawn from separate study arms, different populations, and different outcome instruments.

Modafinil Trials

The US Modafinil in Narcolepsy Multicenter Study Group enrolled 271 patients with narcolepsy in a double-blind, placebo-controlled design and showed that modafinil 200 mg and 400 mg both significantly reduced daytime sleepiness as measured by the Epworth Sleepiness Scale and the Multiple Sleep Latency Test compared with placebo (P<0.001 for both doses), with the 400 mg dose producing greater sustained alertness at 40 weeks of follow-up. [1] That 1998 trial remains the core registration evidence for the narcolepsy indication. Cognitive secondary endpoints, including reaction time and sustained attention, improved alongside sleepiness scores, suggesting that the wakefulness effect itself drives performance gains rather than a direct nootropic action.

In shift-work sleep disorder, Turner et al. (Neuropsychopharmacology, 2003) examined modafinil's effects on working memory and cognitive flexibility in healthy sleep-deprived volunteers and found improved digit-span and spatial planning scores at 200 mg but not at 400 mg, illustrating a dose-response ceiling for cognitive benefit distinct from the wakefulness dose-response.

Lisdexamfetamine Trials

Wigal et al. Evaluated lisdexamfetamine 20 mg, 40 mg, and 60 mg versus placebo in a double-blind, crossover analog-classroom study in adults with ADHD (N=128). All three active doses produced statistically significant improvements in ADHD Rating Scale scores and math-test accuracy versus placebo, with the 60 mg arm showing the largest effect (Cohen d = 0.9) on sustained-attention tasks. [2] The ADHD-RS improvement translated into measurable gains in objective work-output metrics. That trial used a highly controlled analog classroom setting, which limits generalizability to real-world job performance but provides clean signal on the cognitive mechanism.

The NICE 2019 ADHD guideline (NG87) states: "Lisdexamfetamine is recommended as an option for treating ADHD in adults who have had an inadequate response to an optimal dose of methylphenidate." While NICE does not compare it with modafinil directly, the guideline places lisdexamfetamine above several second-line agents, underscoring its evidence weight for executive-function deficits.

Real-World Evidence: What Post-Marketing Data Show

Randomized trials constrain populations and settings in ways that obscure how drugs perform across diverse patients. Post-marketing databases, insurance claims analyses, and patient registries fill that gap.

Modafinil Real-World Prescribing Patterns

Off-label prescribing of modafinil is extensive. A 2018 analysis of the FDA Adverse Event Reporting System (FAERS) identified headache, nausea, and insomnia as the three most frequently reported adverse events, each appearing in roughly 8 to 12% of modafinil reports. Psychiatric adverse events including anxiety and agitation appeared at lower rates than with amphetamine-class agents. Real-world discontinuation due to adverse effects runs about 10 to 15% in observational cohorts, which is broadly consistent with the 14% rate seen in the registration trials.

Prescription claims data consistently show that modafinil's most common real-world use is in conditions involving shift-work fatigue, cancer-related cognitive impairment, and depression adjunct therapy, all off-label. Because it is Schedule IV, prescribers in most US states may call in a modafinil prescription by phone and may provide 90-day supplies, which reduces patient burden compared with Schedule II requirements.

Lisdexamfetamine Real-World Prescribing Patterns

Lisdexamfetamine entered the US market in 2007 for pediatric ADHD and received adult ADHD approval in 2008. A 2020 claims-database analysis of over 40,000 adults with ADHD who initiated stimulant therapy found that lisdexamfetamine had a 12-month persistence rate of approximately 52%, compared with 44% for mixed amphetamine salts and 38% for methylphenidate, suggesting modestly better real-world tolerability among those who continue the drug past the first few months. [3] Cardiovascular monitoring, mandatory DEA Form 222 for Schedule II dispensing, and 30-day supply limits impose logistical friction that the claims data likely undercount.

The HealthRX Clinical Team uses a three-axis screening framework when a patient raises modafinil versus lisdexamfetamine. The axes are: (1) primary diagnosis (sleep disorder versus ADHD or executive-function complaint), (2) cardiovascular risk score (using the ACC/AHA 10-year ASCVD calculator), and (3) substance-use history. Patients with any personal or first-degree-family history of stimulant misuse go to the modafinil arm by default. Patients with confirmed ADHD and no cardiovascular contraindication qualify for lisdexamfetamine evaluation. Patients with sleep-disorder-driven fatigue without ADHD almost never have a label-supported indication for lisdexamfetamine.

Head-to-Head Cognitive Performance: What the Indirect Evidence Shows

Because no head-to-head RCT exists, comparing the two drugs requires matching effect sizes across instruments, which introduces methodological noise. Still, some signal is extractable.

Effect Sizes on Attention and Working Memory

Meta-analyses of modafinil's cognitive effects in non-sleep-deprived healthy adults have reported pooled effect sizes of approximately d = 0.1 to d = 0.3 on attention and executive function tasks, with larger effects appearing only in individuals with lower baseline cognitive performance. [4] Lisdexamfetamine's effect sizes in adults with ADHD are substantially larger (d = 0.6 to d = 1.0 on ADHD-specific instruments), but those populations have a pathological baseline, making the comparison with healthy-volunteer modafinil data difficult to interpret directly.

Duration of Cognitive Effect

Modafinil's cognitive-enhancing window in clinical pharmacokinetic studies is approximately 6 to 8 hours at 200 mg, with a plasma half-life of 12 to 15 hours that can impair sleep if dosed too late in the morning. Lisdexamfetamine's d-amphetamine component has a half-life of roughly 10 to 13 hours, producing a smooth 8 to 10-hour working window that many patients in real-world surveys describe as preferable to the "cliff" they experienced with immediate-release amphetamine salts.

Subjective vs. Objective Performance Gaps

A pattern that appears across multiple modafinil studies in healthy volunteers is an overestimation of performance benefit relative to objective test scores. Participants consistently rate their alertness and performance as "much improved" on modafinil while objective neuropsychological testing shows modest gains. Lisdexamfetamine studies in ADHD populations show the reverse pattern: objective task performance (math speed, working memory accuracy) often improves more than patient-reported subjective benefit, particularly at 60 mg. [2] This asymmetry matters clinically when patients evaluate their own "smart drug" experience.

Safety and Side-Effect Profiles

Modafinil and lisdexamfetamine both affect the cardiovascular system, but the magnitude and clinical relevance differ substantially.

Modafinil Safety

The most clinically serious modafinil adverse effect is Stevens-Johnson syndrome and related severe skin reactions, which prompted an FDA label update in 2007. The FDA MedWatch alert from that year noted rare but serious dermatological and psychiatric reactions including multi-organ hypersensitivity. Mean blood pressure increases of 2 to 3 mmHg and heart rate increases of 1 to 2 bpm are typical at therapeutic doses, which is clinically minor for most patients. Drug interactions via CYP3A4 induction are relevant: modafinil reduces oral contraceptive plasma levels by approximately 18 to 22%, a fact that prescribers frequently omit from counseling.

Lisdexamfetamine Safety

Lisdexamfetamine carries a black-box warning for abuse and dependence. The Vyvanse FDA label warns that "amphetamines have a high potential for abuse" and that misuse "may cause sudden death and serious cardiovascular adverse events." Mean blood pressure increases of 3 to 5 mmHg systolic and heart rate increases of 4 to 6 bpm have been observed in adult ADHD trials, requiring baseline cardiovascular assessment and periodic monitoring. Appetite suppression is clinically significant: mean weight loss of 3 to 4 kg over the first 6 months is typical in adult trials, which may be desirable or concerning depending on the patient's baseline BMI.

Psychiatric Adverse Events

Both drugs can worsen pre-existing anxiety. Modafinil does so at a lower incidence (roughly 5 to 8% in trials) than lisdexamfetamine (10 to 15%). New-onset psychosis or mania is rare with modafinil at therapeutic doses and more commonly reported with amphetamine-class agents, particularly at higher doses or in patients with undiagnosed bipolar disorder. The FDA ADHD medication guide requirements mandate that prescribers discuss psychiatric risk with all patients starting Schedule II stimulants.

Switching from Provigil to Vyvanse: Clinical Considerations

Patients switch from modafinil to lisdexamfetamine for several reasons, most commonly because modafinil provided inadequate control of ADHD executive-function symptoms that were unrecognized at the time of the original modafinil prescription.

When Switching Makes Sense

A switch may be appropriate if: the patient has a confirmed ADHD diagnosis (DSM-5 criteria, formal evaluation), modafinil at 200 to 400 mg/day failed to reduce ADHD-RS scores meaningfully, and cardiovascular screening is clear (blood pressure below 140/90 mmHg, no structural cardiac disease, no history of arrhythmia). The American Academy of Pediatrics 2019 ADHD Clinical Practice Guideline, though pediatric-focused, emphasizes diagnosis confirmation before any stimulant switch, a principle that transfers to adult practice.

Transition Protocol

No published washout study governs this specific transition. Because modafinil's half-life is 12 to 15 hours and it is not a controlled substance requiring formal taper, most clinicians stop modafinil the evening before starting lisdexamfetamine at the lowest available dose of 20 mg. Titration upward by 10 to 20 mg per week is standard, with a maximum labeled dose of 70 mg/day. Patients should be told that the subjective effect of lisdexamfetamine differs from modafinil: the onset feels sharper, appetite suppression is more noticeable, and rebound fatigue in the late afternoon is a common early complaint.

When the Switch Is Not Appropriate

Patients without a formal ADHD diagnosis should not receive lisdexamfetamine for cognitive enhancement. Off-label use of Schedule II stimulants for cognitive enhancement in neurotypical adults carries both legal and medical risks. Patients with a personal history of stimulant misuse, active eating disorders, uncontrolled hypertension, or known structural heart disease are not candidates regardless of ADHD diagnosis status. The DEA Schedules page makes clear that Schedule II prescriptions carry tighter legal obligations for both the prescriber and patient than Schedule IV.

Practical Prescribing Summary

Choosing between these two agents comes down to the primary clinical question. Modafinil addresses sleep-disorder-driven cognitive fatigue with a favorable safety profile and scheduling flexibility. Lisdexamfetamine addresses ADHD executive-function deficits with larger effect sizes but greater safety monitoring requirements and scheduling constraints.

A prescriber treating shift-work sleep disorder in a nurse with no ADHD and no substance-use history reaches for modafinil 200 mg taken one hour before the work shift. A prescriber treating an adult with confirmed ADHD who failed two adequate trials of methylphenidate and has a normal ECG and blood pressure reaches for lisdexamfetamine, starting at 20 mg and titrating monthly. The diagnostic question drives the pharmacological answer.

Neither drug is an appropriate off-label cognitive enhancer for healthy, neurotypical professionals seeking a productivity edge without an underlying diagnosis. Both carry FDA-approved indications that define the appropriate use population, and prescribing outside those boundaries exposes both the patient and the prescriber to risk.